Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Formosa Pharmaceuticals's earnings per share without non-recurring items for the
three
months ended in Dec. 2025 was NT$-0.31.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.54.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 47.80% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 29.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Formosa Pharmaceuticals's EPS without NRI or its related term are showing as below:
TPE:6838'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9.6 Med: 17.9 Max: 47.8
Current: 47.8
During the past 7 years, Formosa Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 47.80% per year. The lowest was -9.60% per year. And the median was 17.90% per year.
TPE:6838's 3-Year EPS without NRI Growth Rate is ranked better than 83.39% of 1168
companies
in the Biotechnology industry
Industry Median: 16.4
vs TPE:6838: 47.80
Formosa Pharmaceuticals (TPE:6838) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Formosa Pharmaceuticals EPS without NRI Related Terms
Formosa Pharmaceuticals EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6838 vs VRTX, REGN, ALNY: EPS without NRI Comparison
For the Biotechnology subindustry, Formosa Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formosa Pharmaceuticals PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Formosa Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Formosa Pharmaceuticals's PE Ratio without NRI falls into.
Formosa Pharmaceuticals EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Formosa Pharmaceuticals (TPE:6838) has a EPS without NRI of NT$-0.54 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Formosa Pharmaceuticals and its competitors. According to the industry distribution chart, Formosa Pharmaceuticals ranks #194 out of 1168 companies in the Biotechnology industry, placing it in the top 16.6%.
Is Formosa Pharmaceuticals' EPS without NRI too high?
Formosa Pharmaceuticals' current EPS without NRI is NT$-0.54. Based on the distribution chart, Formosa Pharmaceuticals ranks #194 out of 1168 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Formosa Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Formosa Pharmaceuticals' EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formosa Pharmaceuticals ranks #194 out of 1168 companies for EPS without NRI. This places Formosa Pharmaceuticals in the top 17% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Formosa Pharmaceuticals and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Formosa Pharmaceuticals's current EPS without NRI is NT$-0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formosa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Formosa Pharmaceuticals (TPE:6838) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.27, compared to a current price of NT$22.80 — trading 59.8% above its estimated fair value. The current EPS without NRI is NT$-0.54. Formosa Pharmaceuticals' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Formosa Pharmaceuticals (TPE:6838), the current EPS without NRI is NT$-0.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formosa Pharmaceuticals (TPE:6838) Overvalued in 2026?
Based on GuruFocus' analysis, Formosa Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$22.80 is trading 59.8% above its estimated GF Value™ of NT$14.27.
GuruFocus considers Formosa Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for TPE:6838:
EPS without NRI: NT$-0.54
GF Value™: NT$14.27 vs. price of NT$22.80 (59.8% above fair value)
No single metric tells the full story. See the TPE:6838 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formosa Pharmaceuticals Inc is engaged in new drug development and transfers. Its Product pipeline includes TSY-110, TSY-120, TSY-310, APP13007 and APP13002.
49GF Score
Get the complete analysis for TPE:6838
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6838 has been successfully added to your 
